Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT03532698
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 40
- Registration Number
- NCT03497767
- Locations
- 🇦🇺
Calvary Mater, Newcastle, New South Wales, Australia
🇦🇺St. Vincents Hospital, Sydney, New South Wales, Australia
🇦🇺Liverpool Hospital, Sydney, New South Wales, Australia
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT03463525
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03455829
- Locations
- 🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 17
- Registration Number
- NCT03434418
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 27
- Registration Number
- NCT03433469
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of California, Davis, Davis, California, United States
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 173
- Registration Number
- NCT03410043
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCSF Medical Center-Mount Zion, San Francisco, California, United States
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT03394118
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT03392246
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 43
- Registration Number
- NCT03381274
- Locations
- 🇨🇳
Research Site, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.